Log in to your Inderes Free account to see all free content on this page.

S2Medical

0.01 SEK

0.00 %

Less than 1K followers

S2M

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

0.00 %

-8.47 %

-17.56 %

-50.91 %

+2.86 %

+13.68 %

-95.36 %

-99.40 %

-99.70 %

S2Medical operates in the medical technology sector. The company is focused on research and development of various wound healing products. Various products offered include cellulose-based materials and dressings for the healing of burns and chronic wounds. The products are sold under various brands, mainly at a European level. S2Medical was founded in 2013 and is headquartered in Linköping.

Market cap

10.12M SEK

Turnover

18.31K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

20.2.

2026

Annual report '25

5.6.

2026

General meeting '26

21.8.

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release6/20/2024, 8:32 AM

S2Medical AB: Epiprotect® Demonstrates Significantly Lower Infection Risk in Major Pediatric Study

Regulatory press release11/6/2023, 3:09 PM

S2Medical AB (publ) Signs Exclusive Distribution Agreement with Provas Medical Ltd for the Turkish Market

Regulatory press release8/25/2023, 1:30 PM

S2Medical AB: INTERIM REPORT APRIL - JUNE 2023

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release7/5/2023, 6:45 AM

S2Medical AB (publ) announces final outcome in the company's rights issue

Regulatory press release7/4/2023, 8:21 AM

S2Medical AB Secures New Loan Agreement and Aims to be Debt-Free by July 2024

Regulatory press release7/3/2023, 4:26 PM

S2Medical AB: S2Medical (publ) announces preliminary outcome in the company's rights issue

Regulatory press release6/16/2023, 11:45 AM

S2Medical AB (publ) publishes a prospectus regarding the rights issue

Regulatory press release6/8/2023, 3:15 PM

S2Medical AB (publ) signs a manufacturing agreement with a distributor in Saudi Arabia

Regulatory press release5/31/2023, 5:00 PM

S2Medical AB: Interim Report January - March 2023

Regulatory press release5/17/2023, 11:33 AM

S2Medical AB (publ) signs a distribution agreement for the Iranian market

Regulatory press release5/16/2023, 2:45 PM

S2Medical AB: S2Medical wins procurement for wound healing items in the Västra Götaland region

Regulatory press release5/10/2023, 9:34 AM

S2Medical AB: Postponing of publication of the quarterly report for the period January to March 2023

Regulatory press release4/24/2023, 3:09 PM

S2Medical AB: Postponement of publication of annual report

Regulatory press release4/21/2023, 1:37 PM

S2Medical AB: S2Medical wins procurement for wound healing items in the United Arab Emirates worth approximately SEK 3.4 million

Regulatory press release4/13/2023, 9:32 AM

S2Medical AB (publ) signs a distributor agreement in the United Arab Emirates and delivers a record order of the skin substitute Epiprotect worth about SEK 2 million

Regulatory press release3/28/2023, 2:36 PM

S2Medical AB: S2Medical implements a strategic change to reach profitability faster

Regulatory press release3/3/2023, 11:39 AM

S2Medical AB: S2Medical wins procurement for wound healing equipment in Region Halland

Regulatory press release2/22/2023, 2:45 PM

Year-end report January - December 2022 S2Medical AB (publ)

Regulatory press release2/16/2023, 4:44 PM

S2Medical AB: Postponing of publication of the year-end report

Regulatory press release1/2/2023, 4:15 PM

S2Medical AB: Positive outcome when S2Medicals antimicrobial peptides were tested against the multi resistant bacteria that by WHO have been defined as a global health threat

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.